ArticleScientific reports2025
KIAA1429 promotes non-small-cell lung cancer cell proliferation through the TRERNA1/HOXA6 axis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway.Human cell · 2026Article
- The role of m6A modification in non-small cell lung cancer: functional insights and impact on therapy resistance.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. This study aimed to investigate the mechanism of vir-like m6A methyltransferase-associated protein (VIRMA, also called KIAA1429) in NSCLC cell proliferation. Levels of KIAA1429, long-chain non-coding RNAs translation regulatory long non-coding RNA 1 (lncRNA TRERNA1), and homeobox A6 (HOXA6) were measured in NSCLC cells and normal cells. The enrichment of KIAA1429 and m6A on lncRNA TRERNA1 was detected. LncRNA TRERNA1 stability and subcellular localization of lncRNA TRERNA1 were detected. The binding of EZH2 to lncRNA TRERNA1 was analyzed. The enrichment of EZH2 and H3K27me3 on the HOXA6 promoter was analyzed. The mechanism of KIAA1429 was validated in vivo. KIAA1429 and lncRNA TRERNA1 were overexpressed in NSCLC cells and HOXA6 was downregulated. Knockdown of KIAA1429 significantly reduced NSCLC cell proliferation. KIAA1429 enhanced lncRNA TRERNA1 RNA stability via m6A modification and upregulated lncRNA TRERNA1 expression, which recruited EZH2 and increased H3K27me3 modification in the HOXA6 promoter region, thus suppressing HOXA6 expression. LncRNA TRERNA1 overexpression or HOXA6 downregulation alleviated the inhibitory effect of KIAA1429 downregulation on NSCLC cell proliferation. KIAA1429 downregulation inhibited NSCLC cell proliferation in vivo. In conclusion, KIAA1429 promotes NSCLC proliferation through the TRERNA1/HOXA6 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.